glp-1 for mash Novo Nordisk Drug Meets Goals of Trial, Setting Stage FDA & EMA Filings Incretin-based therapies in MASLD/MASH: from
Description
Nogueiras, R
Reflections from a diabetes care editors expert forum
Deacon CF (2007) Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
[DOI] [PubMed] [Google Scholar] 6.Andersen DK, Elahi D, Brown JC, Tobin JD, Andres R (1978) Oral glucose augmentation of insulin secretion
